scholarly journals Disaharidase deficiency – is one of the causes of functional disorders of intestine.

2018 ◽  
Vol 96 (4) ◽  
pp. 365-370
Author(s):  
Asfold I. Parfenov ◽  
O. V. Ahmadullina ◽  
N. I. Belostoskij ◽  
E. A. Sabelnikova ◽  
S. V. Bykova ◽  
...  
Keyword(s):  
Bowel Disease ◽  
Functional Constipation ◽  
Normal Activity ◽  
Functional Bowel Disease ◽  
Functional Diarrhea ◽  
Intestinal Infections ◽  
Bowel Diseases ◽  
Activity Of Enzymes ◽  
Irritable Bowel ◽  
Duodenal Biopsies

The aim of the study was to show the importance of intestinal carbohydrase (glucoamylase, maltase, sucrase and lactase) in the etiology and pathogenesis of functional bowel diseases. Material and methods. It was examined 74 patients with FBD in age from 18 to 50 years (36 men and 38 women.). According to Rome IV criteria (2016) 21 had irritable bowel syndrome (IBS) with predominance of diarrhea , 33 functional diarrhea, 6 - IBS with predominant constipation , 4 functional constipation and 10 IBS mixed type. Karbohidrase activity in mucosa of the small intestine was investigated by the method of Dahlquist modification Trinder in duodenal biopsies obtained during esophagogastroduodenoscopy. Results. Lactase deficiency identified in 87.8%, maltasa - 48.6 percent, saharasia - 51,3%, the lack of glucoamylase - in 85.1% of patients. The activity of all investigated enzymes was reduced in 23 (31.1%) patients with functional bowel disease. Normal activity of enzymes have 4 (5,4%) patients. Conclusion. In 70 of 74 patients with functional bowel disease violations of the chair, abdominal pain and flatulence due to the decrease in the activity of carbohydrase of mucosa. The reason of disaccharidase deficiency may be due to the acute intestinal infections, antibiotic and medicine (NSAIDs) treatment.

scholarly journals Disaccharidase deficiency and functional bowel diseases

2017 ◽  
Vol 89 (4) ◽  
pp. 45-52 ◽  
Author(s):  
A I Parfenov ◽  
O V Akhmadullina ◽  
E A Sabelnikova ◽  
N I Belostotsky ◽  
M V Kirova ◽  
...  
Keyword(s):  
Functional Constipation ◽  
Biopsy Specimens ◽  
Functional Diarrhea ◽  
Intestinal Infections ◽  
Bowel Diseases ◽  
Precise Diagnosis ◽  
Intestine Mucosa ◽  
Inflammatory Drugs ◽  
Irritable Bowel

Aim. To elucidate the role of intestinal carbohydrases (glucoamylase, maltase, sucrose, and lactase) in the etiology and pathogenesis of functional bowel diseases (FBD). Subjects and methods. 74 patients (36 men and 38 women) aged 18 to 50 years with FBD were examined. According to Rome IV criteria (2016), there was diarrhea-predominant irritable bowel syndrome (IBS) in 21 patients, functional diarrhea (FD) in 33, constipation-predominant IBS in 6, functional constipation (FC) in 4, and mixed IBS in 10. The activity of carbohydrases in the small intestine mucosa (SIM) was investigated by the Dahlquist method modified by Trinder in the duodenal biopsy specimens obtained during esophagogastroduodenoscopy. Results. Lactase deficiency was identified in 87.8% of the patients; maltase deficiency in 48.6%; sucrose deficiency in 51.3%; and glucoamylase deficiency in 85.1%. The activity of all the investigated enzymes was reduced in 23 (31.1%) patients with FBD; deficiency of 1—3 carbohydrases was found in 47 (63.5%). Normal enzymatic activity was established in 4 (5.4%) patients. Conclusion. In the majority of patients with FBD, the intestinal symptoms are caused by the decreased activity of SIM carbohydrases. Therefore, disaccharidase deficiency associated with an established damaging agent (nonsteroidal anti-inflammatory drugs, antibiotics, acute intestinal infections, etc.) should be considered to be a more precise diagnosis.

scholarly journals Rebamipide increases the disaccharidases activity in patients with enteropathy with impaired membrane digestion. Pilot study

2019 ◽  
Vol 91 (2) ◽  
pp. 25-31 ◽  
Author(s):  
A I Parfenov ◽  
N I Belostotsky ◽  
S G Khomeriki ◽  
O V Akhmadullina ◽  
S V Bykova ◽  
...  
Keyword(s):  
Clinical Signs ◽  
Functional Constipation ◽  
Duodenal Mucosa ◽  
Control Group ◽  
Activity Increase ◽  
Functional Diarrhea ◽  
Irritable Bowel ◽  
Fodmap Diet ◽  
Duodenal Biopsies ◽  
Rome Iv

Aim. To evaluate the effectiveness of enteroprotector Rebamipide in the treatment of enteropathy with impaired membrane digestion (EIMD). Materials and methods. We examined 102 patients aged 18 to 50 years (41 men and 61 women) with clinical signs of irritable bowel syndrome (n=65), functional diarrhea (n=33), and functional constipation (n=4) according to Rome IV criteria (2016). The activities of glucoamylase (GA), maltase, sucrase and lactase were determined by Dahlquist-Trinder method in duodenal biopsies obtained during esophagogastroduodenoscopy. The control group consisted of 20 healthy people aged 23-47. They showed following average enzyme activity: lactase - 42±13 ng glucose on 1 mg of tissue per minute, GA - 509±176, maltase - 1735±446, sucrase - 136±35 ng glucose on 1 mg of tissue per minute. These numbers were taken as the norm. Results and discussion. The activity of the disaccharidases was reduced in 89.2% out of 102 patients, and they were diagnosed with EIMD. Thirteen patients with EIMD were recommended to maintain the FODMAP diet and take enteroprotector Rebamipide 100 mg 3 times a day for 12 weeks. After 3 months 11 patients reported decreased or no flatulence, abdominal pain, stool disorder; 2 patients reported no change. The activity of GA increased to an average of 149±82 (by 78%, p=0.016), maltase - to 864±472 (by 131%, p=0.0019), sucrase - 63±35 (by 95%, p=0.0041) and lactase - 10±8 ng glucose on 1 mg of tissue per minute. The activity of lactase did not change. Conclusion. We discovered a previously unknown phenomenon of the disaccharidases activity increase in duodenal mucosa and improved carbohydrates tolerance in the patients with EIMD taking Rebamipide in the dose 300 mg/day for 12 weeks.

Effect of a synbiotic, ColonFit, in patients with irritable bowel syndrome, functional constipation and functional diarrhea

2020 ◽  
Vol 74 (6) ◽  
pp. 535-542
Author(s):  
Radek Kroupa ◽  
Jiří Jarkovský ◽  
Barbora Packová ◽  
Šárka Doležalová ◽  
Hana Junková ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Functional Constipation ◽  
Bowel Symptoms ◽  
Functional Diarrhea ◽  
Initial Symptoms ◽  
Bowel Diseases ◽  
Bowel Movements ◽  
Bristol Stool Scale ◽  
Irritable Bowel

Background: Supplementary dietary fiber and probiotics may improve bowel symptoms due to changes in microbiome and fermentation. The aim of the study was the evaluation of symbiotic with psyllium, ColonFit, in patients with functional colonic diseases. Patients and Methods: A prospective observational study in patients with irritable bowel syndrome, functional constipation and functional diarrhea for a 4-week intake of ColonFit 10 g daily. The type and severity of bowel symptoms (scale 1–5), number and consistency of stool and quality of life features were analyzed in subgroups according to dominant initial symptoms. Results: Complete data were available from 110 patients (mean age 49.9 ± 15.3 years, 58.2% females). Constipation related symptoms were predominant in 46 (41.8%) patients, diarrhea in 28 (25.5%) and mixed type in the rest. The symptoms in constipation predominant group were more severe than in others. The significant change in softening of stool consistency (from 1.9 to 3.8 in Bristol stool scale; p < 0.001), an increase in spontaneous bowel movements (from 3.1 to 5.6× weekly; p = 0,001) and reduction of incomplete bowel movements of 40% and abdominal pain of 42% were observed in constipated patients. The reduction in a number of bowel movement per week (from 17.8 to 13.6; p = 0.001) and improvement of abdominal cramps by 27% and reduction of dietary limitations by 30% were recorded in diarrhea subgroup. The beneficial effect lasted for a two-week follow up after the discontinuation of ColonFit use. Conclusion: The ColonFit use was most beneficial in constipated patients. The improvement of several symptoms was observed in other subtypes of irritable bowel syndrome without any worsening of troubles. The use of the combination of psyllium, inulin and probiotics may offer an effective alternative for the management of functional bowel diseases.

scholarly journals Inflammatory Bowel Diseases and Irritable Bowel Syndrome: Overlap of Two Nosological Forms or Two Variants of the Same Disease?

2019 ◽  
Vol 29 (5) ◽  
pp. 43-48
Author(s):  
A. A. Sheptulin ◽  
K. E. Vinogradskaya
Keyword(s):  
Inflammatory Bowel Disease ◽  
Irritable Bowel Syndrome ◽  
Inflammatory Bowel Diseases ◽  
Bowel Disease ◽  
High Incidence ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Irritable Bowel ◽  
The Relationship

Aim. To review available literature data on the relationship between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).Key findings. Current publications on IBD and IBS present different viewpoints on their relationship. Thus, researchers have noted a high incidence of IBD against the background of IBS, frequent persistence of IBS-like symptoms after achieving IBD remission, as well as the possibility of overlapping the diseases. According to literature data, IBD and IBS should be treated as different forms of the same disease. An opinion is expressed that IBS-like complaints in patients with IBD remission should be considered as a separate disease referred to as “irritated inflammatory intestinal syndrome”. Treatment of IBS-like symptoms in patients with IBD remission has thus far not been developed.Conclusion. The problem of the relationship between IBD and IBS is currently controversial, thus requiring further clarification.

scholarly journals Clinical and metabolic effects of metaprebiotic therapy for some functional bowel diseases

2021 ◽  
pp. 100-108
Author(s):  
O. N. Minushkin ◽  
L. V. Maslovsky ◽  
M. D. Ardatskaya ◽  
M. I. Bulanova ◽  
N. I. Beilina ◽  
...  
Keyword(s):  
Abdominal Pain ◽  
Lactic Acid ◽  
Adverse Events ◽  
Butyric Acid ◽  
Functional Constipation ◽  
Stool Frequency ◽  
Metabolic Effects ◽  
Functional Diarrhea ◽  
Before And After ◽  
Bowel Diseases

Aim of investigation: to assess the effectiveness and tolerance of dietary supplements (BAA) STIM and STIM LaxMaterials and methods: The analysis of the treatment of 73 patients who were divided into 2 groups. Group 1-32 patients with functional constipation (8 men and 24 women; mean age — 45.7 ± 12.4 years), Group 2-41 patients with functional diarrhea (19 men and 22 women; mean age — 41.0 ± 15,8 years). The study of clinical symptoms was carried out according to the data of an individual diary, using specialized questionnaires with a scoring of symptoms before and after the course of treatment, before and after treatment, the result of the carbolene test, the content of short-chain fatty acids in the feces was assessed. Tolerability was assessed by recording side effects and adverse events.Monotherapy was carried out with STIM LAX for patients with functional constipation at a dose of 1 tablet 3 times a day for 30 days. STIM for patients with functional diarrhea was prescribed in a dose of 2 tablets 3 times a day for 30 days.Results of the study: The results of the study showed that FC therapy with StimLax effectively reduces the frequency and intensity of symptoms such as difficulty / pain, discomfort during defecation, feeling of incomplete emptying, abdominal pain, time spent in the toilet and the number of failed bowel movements. We observed the normalization of transit time according to the carbolene test and an increase in stool frequency up to 5 times a week.Treatment of patients with FD with Stim led to a significant decrease in the intensity of abdominal pain, rumbling, flatulence, stool frequency, an increase in the time of the carbolene test and the normalization of its consistency.Adverse events were observed in 8 (10.9%) patients (4 patients with FD and 4 patients with FD). On the 3-5th day of treatment, there was an increase in flatulence, rumbling in the abdomen. A temporary decrease in the dose of the drug to 1-2 tablets per day removed these phenomena and the symptoms that appeared were resolved within 1-3 days. After that, the dose of the drug was gradually increased to the initial (effective), which the patients tolerated normally.Conclusions: The results of this study indicate high clinical efficacy and good tolerability of treatment with drugs StimLax and Stim in patients with FC and FD. In some cases, it is necessary to titrate the dose of the drug (downward), but this is not accompanied by a decrease in the effectiveness of therapy. The use of these drugs with metaprebiotic properties helps to modify the microbiota of patients with functional bowel diseases. With constipation, the number and activity of both lactic acid flora and microorganisms that produce butyric acid are stimulated; in addition, calcium lactate is an additional source of butyric acid due to metabolism. With diarrhea, along with the stimulation of the number and activity of the lactic acid flora, there is an improvement in the utilization of butyrate by intestinal cells.

Debatable aspects of pathogenesis and diagnostics of irritable bowel syndrome (IBS) and inflammatory bowel diseases with IBS-like diseases

2016 ◽  
Vol 94 (10) ◽  
pp. 795-800
Author(s):  
A. P. Pogromov ◽  
Ol’ga, V. Tashchyan ◽  
M. G. Mnatsakanyan ◽  
G. M. Dyukova
Keyword(s):  
Inflammatory Bowel Disease ◽  
Irritable Bowel Syndrome ◽  
Differential Diagnosis ◽  
Bowel Disease ◽  
Inflammatory Disorder ◽  
Controversial Issues ◽  
Key Points ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Irritable Bowel

Aim of review: To analyze current publications devoted to controversial issues of pathogenesis, diagnosis and differential diagnosis of irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) in remission with IBS-like symptoms. Key points: There are three main hypotheses discussed in the literature: 1) IBS as a prodrome, pre-stage of the IBD; 2) IBS and IBD are different variants of inflammatory disorder which is common to both diseases; 3) The onset of IBS-like symptoms in IBD patients in remission. Conclusion: It is shown that modern literature data on this issue is contradictory and ambiguous.

Sign in / Sign up

Export Citation Format

Share Document